<DOC>
	<DOCNO>NCT01399255</DOCNO>
	<brief_summary>The aim study assess bioequivalence two rapid-acting insulin Lispro formulation : Humalog® Listro™ healthy subject base pharmacokinetic parameter ( PK ) pharmacodynamic parameter ( PD ) .</brief_summary>
	<brief_title>Comparative Bioequivalence Study Wockhardt 's Insulin Analogue Lispro ( Listro™ ) With Humalog® Healthy Subjects</brief_title>
	<detailed_description>The purpose study assess bioequivalence two rapid-acting insulin Lispro formulation : Humalog® Listro™ healthy subject , base pharmacokinetic parameter ( PK ) AUC ( INS-LIS 0-8h ) pharmacodynamic parameter ( PD ) AUC ( GIR 0-8h ) also assess safety local tolerability two insulin preparation .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>1 . Healthy male female subject . 2 . Age ≥18 ≤50 year . 3 . Considered generally healthy upon completion medical history , physical examination biochemical investigation judge Investigator . 4 . Body Mass Index ( BMI ) 18.0 27.0 kg/m2 , inclusive . 5 . Nonsmoker , define nicotine consumption least one year . 6 . Signed date informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) 1 . Previous participation trial clinical trial within last 30 day . 2 . Pregnant , breastfeed intention become pregnant use adequate contraceptive measure ( e.g . intrauterine device ( IUD ) place least 3 month , sterilization , oral contraceptive pill , take without difficulty least 3 month , approve hormonal implant double barrier method ) include male condom use plus spermicide , diaphragm spermicide plus male condom cap spermicide plus male condom acceptable option ) . 3 . Clinically significant abnormal hematology biochemistry screen test , judge Investigator . In particular , subject elevate fast blood glucose , elevate liver enzyme ( AST ALT &gt; 2 time upper limit normal ) impair renal function ( elevate serum creatinine value upper limit allow enter trial . Subjects abnormal TSH may require additional testing thyroid hormone clarification . Subjects abnormal TSH judge Investigator clinically significant exclude study . 4 . Any serious systemic infectious disease four week prior first dose test drug , judge Investigator . 5 . History illness , opinion Investigator , might confound result trial pose risk administer trial drug subject . In particular , subject significant cardiovascular disease , anemia ( hemoglobin low limit normal ) hemoglobinopathy allow enter trial . 6 . Cardiac problem define decompensated heart failure ( New York Heart Association ( NYHA ) class III IV ) time and/or angina pectoris within last 12 month and/or acute myocardial infarction time . 7 . Clinically significant abnormal ECG screening , judge Investigator . 8 . History alcohol drug abuse past five year . 9 . Any positive screen drug abuse . 10 . Hepatitis B C HIV positive . 11 . Use prescription drug within 3 week precede first dose insulin , except oral contraceptives/hormonal implant . 12 . Use nonprescription drug , except routine vitamin herbal product , within 3 week prior first dose test drug . 13 . Occasional use acetaminophen permit . Acetaminophen allow dose day 4 hour postdosing . 14 . Use systemic corticosteroid , monoamine oxidase ( MAO ) inhibitor , prostaglandin blocker , systemic nonselective betablockers , growth hormone 15 . Thyroid hormone allow unless stable past 3 month . 16 . Any use nonsteroid antiinflammatory drug ( NSAIDs ) except lowdose Aspirin allow within 7 day prior dose dose day . 17 . Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation . 18 . Blood donation 500 ml within last 12 week . 19 . History multiple and/or severe allergy drug food history severe anaphylactic reaction . 20 . Known suspect allergy trial product relate product . 21 . History deep leg vein thrombosis frequent appearance deep leg vein thrombosis 1st degree relative ( parent , sibling child ) judge Investigator . 22 . Any disease condition , opinion Investigator , would represent unacceptable risk subject 's safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>